As a long‐acting insulin analog, insulin glargine (IGlar) is characterized by a longer duration of action and with a less‐pronounced peak, effectively reducing HbA1c and fasting plasma glucose (FPG); the risk of hypoglycemia, especially nocturnal hypoglycemia, is significantly lower than with neutral protamine Hagedorn insulin.6, 7. The gene discussed is INS; the disease is Hypoglycemia.